What daraxonrasib is
Daraxonrasib is an oral drug developed by Revolution Medicines that inhibits RAS proteins in their active, signal-sending ("ON") state. RAS proteins act like switches that tell cells to grow. Mutations can lock them on, and RAS mutations drive most pancreatic cancers as well as many lung and colorectal cancers.
For decades RAS was considered "undruggable" because its surface offered few places for a drug to bind. Earlier approved RAS drugs target a single mutation, KRAS G12C, which is uncommon in pancreatic cancer. Daraxonrasib is designed to act across multiple RAS mutations, which is why it matters so much for pancreatic cancer. See What Are Genetic Mutations?
Clinical evidence
Phase 1/2
In the Phase 1/2 study published in the New England Journal of Medicine in 2026, 168 patients with pancreatic cancer received daraxonrasib at 300 mg or less:
- Among 26 patients with RAS G12 mutations treated second-line at 300 mg, 35% had an objective response. Median progression-free survival was 8.5 months and median overall survival 13.1 months.
- Treatment-related adverse events occurred in 96% of patients and were grade 3 or higher in 30%. The most common were rash, diarrhea, nausea, mouth sores, vomiting, and fatigue.
Phase 3: RASolute 302
| Measure | Daraxonrasib | Standard chemotherapy |
|---|---|---|
| Patients randomized | 500 in total (1:1) | |
| Median overall survival | 13.2 months | 6.7 months |
| Overall survival hazard ratio | 0.40 (95% CI 0.30–0.53) | |
| Median progression-free survival | 7.2 months | 3.6 months |
| Progression-free survival hazard ratio | 0.49 (95% CI 0.38–0.64) |
Source: FDA approval announcement, August 26, 2026.
A hazard ratio of 0.40 means a 60% lower risk of death at any point during follow-up. That is an unusually large effect for metastatic pancreatic cancer, where treatment advances are typically measured in weeks.
Regulatory status
The FDA approved Rasonque (daraxonrasib) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. According to the FDA:
- the recommended dose is 300 mg once daily by mouth,
- the drug had Breakthrough Therapy and Orphan Drug designations,
- the application was reviewed under the Commissioner's National Priority Voucher pilot and the Real-Time Oncology Review pilot, and
- it was approved about 6.5 months ahead of the FDA goal date.
The label includes warnings for skin and soft-tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation, lung inflammation, and harm to a developing fetus. Revolution Medicines has also announced European Commission approval (company-reported).
Scientific perspective
Daraxonrasib supports a theme in modern oncology: drugs aimed at a validated genetic driver can work dramatically better than conventional therapy. Here, the driver is present in most pancreatic tumors, so the potential reach is broad. The approval rests on a randomized Phase 3 trial with overall survival as a measure, the strongest kind of evidence, which contrasts with programs relying on progression-free survival alone.
Development perspective
- Approved use: previously treated metastatic pancreatic cancer. No benchmark is shown for an approved program.
- Expansion: Phase 3 trials in earlier-line pancreatic cancer and in RAS-mutant lung cancer could substantially widen its use.
- Tolerability: frequent skin, mouth, and gastrointestinal side effects will shape how it is used in practice.
Development timeline
- May 7, 2026Phase 1/2 results published: 35% response rate and 13.1-month median overall survival in second-line RAS G12-mutant pancreatic cancer at 300 mg. Peer-reviewed
- Jun 2026RASolute 302 Phase 3 trial reaches primary completion (estimated in the registry). Registry
- Aug 26, 2026FDA approves Rasonque (daraxonrasib) for previously treated metastatic pancreatic adenocarcinoma: overall survival 13.2 vs 6.7 months (HR 0.40). Regulator
What could change the outlook
- Results of RASolute 303, 304, and 309, which test daraxonrasib in other pancreatic cancer settings, including earlier treatment.
- RASolve 301 in RAS-mutant lung cancer, which could extend use beyond pancreatic cancer.
- Real-world tolerability, since skin, mouth, and gastrointestinal side effects were common in trials.
- Combination studies, including a collaboration with Summit's ivonescimab mentioned in Summit's disclosures.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Daraxonrasib. Company-reported, not independently verified.
- RegulatoryCompany-reportedNov 16, 2026
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Complete Response Letter Received from FDA for BLA
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally...
- Quarterly reportCompany-reportedNov 4, 2026
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and...
The company will continue to provide more details in the coming months with respect to additional Phase III studies evaluating ivonescimab beyond NSCLC, CRC, UC, RCC, BTC, and head and neck squamous cell carcinoma (HNSCC). • In addition to the multiregional studies conducted and sponsored by Summit, Akeso is...
- Quarterly reportCompany-reportedNov 4, 2026
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union,” said Mark A.